NLO-QCD Corrections to Dilepton Production in the Randall-Sundrum Model

The dilepton production process at hadron colliders in the Randall-Sundrum (RS) model is studied at next-to-leading order in QCD. The NLO-QCD corrections have been computed for the virtual graviton exchange process in the RS model, in addition to the usual gamma, Z-mediated processes of standard Drell-Yan. K-factors for the cross-sections at the LHC and Tevatron for differential in the invariant mass, Q, and the rapidity, Y, of the lepton pair are presented. We find the K-factors are large over substantial regions of the phase space.Comment: 24 pages, 12 figure

The Radiated Energy Budget of Chromospheric Plasma in a Major Solar Flare Deduced From Multi-Wavelength Observations

This paper presents measurements of the energy radiated by the lower solar atmosphere, at optical, UV, and EUV wavelengths, during an X-class solar flare (SOL2011-02-15T01:56) in response to an injection of energy assumed to be in the form of nonthermal electrons. Hard X-ray observations from RHESSI were used to track the evolution of the parameters of the nonthermal electron distribution to reveal the total power contained in flare accelerated electrons. By integrating over the duration of the impulsive phase, the total energy contained in the nonthermal electrons was found to be $>2\times10^{31}$ erg. The response of the lower solar atmosphere was measured in the free-bound EUV continua of H I (Lyman), He I, and He II, plus the emission lines of He II at 304\AA\ and H I (Ly$\alpha$) at 1216\AA\ by SDO/EVE, the UV continua at 1600\AA\ and 1700\AA\ by SDO/AIA, and the WL continuum at 4504\AA, 5550\AA, and 6684\AA, along with the Ca II H line at 3968\AA\ using Hinode/SOT. The summed energy detected by these instruments amounted to $\sim3\times10^{30}$ erg; about 15% of the total nonthermal energy. The Ly$\alpha$ line was found to dominate the measured radiative losses. Parameters of both the driving electron distribution and the resulting chromospheric response are presented in detail to encourage the numerical modelling of flare heating for this event, to determine the depth of the solar atmosphere at which these line and continuum processes originate, and the mechanism(s) responsible for their generation.Comment: 14 pages, 18 figures. Accepted for publication in Astrophysics Journa

Utilization of various industrial wastes for the production of poly-b-hydroxy butyrate (PHB) by Alcaligenes eutrophus

Considering the industrial interest of poly-b-hydroxy butyrate (PHB) and its high production cost, work has been undertaken for the production of PHB by Alcaligenes eutrophus. Different industrial wastes (malt, soya, sesame, molasses, bagasse and pharmaceutical waste) were used as a cheap substrate to minimize the production of cost and nitrogen limited minimal agar synthetic medium was also used for comparison. Accumulation of PHB granules in the organism was analyzed by sudan black method. ThePHB production in various industrial waste based medium and nitrogen limited minimal agar synthetic medium was studied by crotonic acid method. The pure form of PHB was collected and qualitatively analyzed by infrared and nuclear magnetic resonance methods. Highest PHB production was found innitrogen limited minimal agar synthetic medium. Among the various industrial wastes based media, highest yield was obtained with sesame oil waste as carbon sourc

Exoplanet diversity in the era of space-based direct imaging missions

Community White Paper: submitted to the National Academy of Sciences Exoplanet Science StrategyThis white paper discusses the diversity of exoplanets that could be detected by future observations, so that comparative exoplanetology can be performed in the upcoming era of large space-based flagship missions. The primary focus will be on characterizing Earth-like worlds around Sun-like stars. However, we will also be able to characterize companion planets in the system simultaneously. This will not only provide a contextual picture with regards to our Solar system, but also presents a unique opportunity to observe size dependent planetary atmospheres at different orbital distances. We propose a preliminary scheme based on chemical behavior of gases and condensates in a planet's atmosphere that classifies them with respect to planetary radius and incident stellar flux

Science cases for a visible interferometer

High spatial resolution is the key for the understanding various astrophysical phenomena. But even with the future E-ELT, single dish instruments are limited to a spatial resolution of about 4 mas in the visible. For the closest objects within our Galaxy most of the stellar photosphere remains smaller than 1 mas. With the success of long baseline interferometry these limitations were soom overcome. Today low and high resolution interferometric instruments on the VLTI and CHARA offer an immense range of astrophysical studies. Combining more telescopes and moving to visible wavelengths broadens the science cases even more. With the idea of developing strong science cases for a future visible interferometer, we organized a science group around the following topics: pre-main sequence and main sequence stars, fundamental parameters, asteroseismology and classical pulsating stars, evolved stars, massive stars, active galactic nuclei (AGNs) and imaging techniques. A meeting was organized on the 15th and 16th of January, 2015 in Nice with the support of the Action Specific in Haute Resolution Angulaire (ASHRA), the Programme National en Physique Stellaire (PNPS), the Lagrange Laboratory and the Observatoire de la Cote d'Azur, in order to present these cases and to discuss them further for future visible interferometers. This White Paper presents the outcome of the exchanges. This book is dedicated to the memory of our colleague Olivier Chesneau who passed away at the age of 41

The ATLAS inner detector trigger performance in pp collisions at 13TeV during LHC Run 2

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, los autores pertenecientes a la UAM y el nombre del grupo de colaboración, si lo hubiereThe designand performance of the inner detector trigger for the high level trigger of the ATLAS experiment at the Large Hadron Collider during the 2016–2018 data taking period is discussed. In 2016, 2017, and 2018 the ATLAS detector recorded35.6fb−1,46.9fb−1,and60.6fb−1 respectively of proton–proton collision data at a centre-of-mass energy of 13TeV. In order to deal with the very high interaction multiplicities per bunch crossing expected with the 13TeV collisions the inner detector trigger was redesigned during the long shutdown of the Large Hadron Collider from 2013 until 2015. An overview of these developments is provided and the performance of the tracking in the trigger for the muon, electron, tau and b-jet signatures is discussed. The high performance of the inner detector trigger with these extreme interaction multiplicities demonstrate show the inner detector tracking continues to lie at the heart of the trigger performance and is essential in enabling the ATLAS physics programm

Satirn as pesticide inhibitor for the corrosion of the galvanized iron in wastewater and its biological effect on Escherichia coli

Satirn is a type of the pesticides has been evaluated as green inhibitor for the corrosion of the galvanized iron in saline solution which was investigated by chemical and electrochemical measurements. The results of polarization showed that satirn acts as mixed type inhibitor. Inhibition was found to increase with the increase of satirn concentration reaching to approximately 90% at 250 ppm. The inhibitive action was discussed by the adsorption of a stable complex on the metal surface. The adsorption of satirn on the metal surface obeys Temkin adsorption isotherm. Satirn has a slightly effect on Escherichia Coli and can be applied safely in sanitation plants

Good practice recommendations on add-ons in reproductive medicine

STUDY QUESTION: Which add-ons are safe and effective to be used in ART treatment? SUMMARY ANSWER: Forty-two recommendations were formulated on the use of add-ons in the diagnosis of fertility problems, the IVF laboratory and clinical management of IVF treatment. WHAT IS KNOWN ALREADY: The innovative nature of ART combined with the extremely high motivation of the patients has opened the door to the wide application of what has become known as 'add-ons' in reproductive medicine. These supplementary options are available to patients in addition to standard fertility procedures, typically incurring an additional cost. A diverse array of supplementary options is made available, encompassing tests, drugs, equipment, complementary or alternative therapies, laboratory procedures, and surgical interventions. These options share the common aim of stating to enhance pregnancy or live birth rates, mitigate the risk of miscarriage, or expedite the time to achieving pregnancy. STUDY DESIGN, SIZE, DURATION: ESHRE aimed to develop clinically relevant and evidence-based recommendations focusing on the safety and efficacy of add-ons currently used in fertility procedures in order to improve the quality of care for patients with infertility. PARTICIPANTS/MATERIALS, SETTING, METHODS: ESHRE appointed a European multidisciplinary working group consisting of practising clinicians, embryologists, and researchers who have demonstrated leadership and expertise in the care and research of infertility. Patient representatives were included in the working group. To ensure that the guidelines are evidence-based, the literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, recommendations were based on the professional experience and consensus of the working group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 46 independent international reviewers. A total of 272 comments were received and incorporated where relevant. MAIN RESULTS AND THE ROLE OF CHANCE: The multidisciplinary working group formulated 42 recommendations in three sections; diagnosis and diagnostic tests, laboratory tests and interventions, and clinical management. LIMITATIONS, REASONS FOR CAUTION: Of the 42 recommendations, none could be based on high-quality evidence and only four could be based on moderate-quality evidence, implicating that 95% of the recommendations are supported only by low-quality randomized controlled trials, observational data, professional experience, or consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS: These guidelines offer valuable direction for healthcare professionals who are responsible for the care of patients undergoing ART treatment for infertility. Their purpose is to promote safe and effective ART treatment, enabling patients to make informed decisions based on realistic expectations. The guidelines aim to ensure that patients are fully informed about the various treatment options available to them and the likelihood of any additional treatment or test to improve the chance of achieving a live birth. STUDY FUNDING/COMPETING INTEREST(S): All costs relating to the development process were covered from ESHRE funds. There was no external funding of the development process or manuscript production. K.L. reports speakers fees from Merck and was part of a research study by Vitrolife (unpaid). T.E. reports consulting fees from Gynemed, speakers fees from Gynemed and is part of the scientific advisory board of Hamilton Thorne. N.P.P. reports grants from Merck Serono, Ferring Pharmaceutical, Theramex, Gedeon Richter, Organon, Roche, IBSA and Besins Healthcare, speakers fees from Merck Serono, Ferring Pharmaceutical, Theramex, Gedeon Richter, Organon, Roche, IBSA and Besins Healthcare. S.R.H. declares being managing director of Fertility Europe, a not-for-profit organization receiving financial support from ESHRE. I.S. is a scientific advisor for and has stock options from Alife Health, is co-founder of IVFvision LTD (unpaid) and received speakers' fee from the 2023 ART Young Leader Prestige workshop in China. A.P. reports grants from Gedeon Richter, Ferring Pharmaceuticals and Merck A/S, consulting fees from Preglem, Novo Nordisk, Ferring Pharmaceuticals, Gedeon Richter, Cryos and Merck A/S, speakers fees from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, Theramex and Organon, travel fees from Gedeon Richter. The other authors disclosed no conflicts of interest. DISCLAIMER: This Good Practice Recommendations (GPRs) document represents the views of ESHRE, which are the result of consensus between the relevant ESHRE stakeholders and are based on the scientific evidence available at the time of preparation.ESHRE GPRs should be used for information and educational purposes. They should not be interpreted as setting a standard of care or bedeemedinclusive of all proper methods of care, or be exclusive of other methods of care reasonably directed to obtaining the same results.Theydo not replace the need for application of clinical judgement to each individual presentation, or variations based on locality and facility type.Furthermore, ESHRE GPRs do not constitute or imply the endorsement, or favouring, of any of the included technologies by ESHRE

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

Background: The treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a challenge with inferior progression free survival (PFS) reported to subsequent treatments. We therefore sought to describe the natural history of MM patients following lenalidomide in the real world. Methods: This was a retrospective cohort review of patients with relapsed MM who received lenalidomide-based treatments in the U.K. Data were collected for demographics, subsequent therapies, treatment responses, survival outcomes and clinical trial enrollment. Results: 198 patients received lenalidomide-based treatments at a median of 2 prior lines of therapy at a median of 41 months (range 0.5-210) from diagnosis. 114 patients (72% of 158 evaluable) became refractory to lenalidomide. The overall survival (OS) after lenalidomide failure was 14.7 months having received between 0-6 subsequent lines of therapy. Few deep responses were observed with subsequent treatments and the PFS to each further line was < 7 months. There was a steep reduction in numbers of patients able to receive further treatment, with an associated increase in number of deaths. The OS of patients progressing on lenalidomide who did not enter a clinical trial incorporating novel agents was very poor (8.8 months versus 30 months, p 0.0002), although the trials group were a biologically fitter group. Conclusion: These data demonstrate the poor outcomes of patients failing lenalidomidebased treatments in the real world, the highlight need for more effective treatments

Pengaruh Konsentrasi Bumbu Dan Gula Imerah Pada Pembuatan Kecap Manis Whey Terhadap Kualitas Fisik Dan Kimia

Penelitian ini dilaksanakan di Laboratorium Sentral Ilmu dan Teknologi Pangan, Laboratorium Teknologi Hasil Ternak, Fakultas Petemakan dan Laboratorium Teknologi Hasil Pertanian, Fakultas Teknologi Pertanian, Universitas Brawijaya pada tanggal 1 Maret- 31 Mei 2007. Tujuan dari penelitian ini adalah untuk mengetahui pengaruh penambahan bumbu dan gula merah pada pembuatan kecap manis dari whey ditinjau dari kualitas fisik dan kimia yaitu total glukosa, total padatan terlarut, berat jenis dan tingkat kecerahan wama (L*). Kegunaan penelitian ini adalah memberikan masukan, informasi dan pengembangan teknologi hasil ternak berupa produk olahan dari whey kepada masyarakat dan menghasilkan produk kecap dari whey yang berkualitas baik yaitu produk yang disukai konsumen dan memenuhi standar kualitas yang berlaku. Materi penelitian adalah kecap whey yang dibuat dari whey keju, bumbu - bumbu dan gula merah. Penelitian ini menggunakan percobaan faktorial (2 x 3) dengan Rancangan Acak Kelompok (RAK). Faktor pertama adalah penggunaan bumbu 5% (Al) dan 10% (A2) dari volume whey. Faktor kedua adalah penggunaan gula merah 40% (Bl ), 50% (B2) dan 60% (B3). Variabel yang diukur adalah total glukosa, total padatan terlarut, berat jenis dan tingkat kecerahan wama. Data dianalisa dengan sidik ragam dan jika terdapat perbedaan di antara perlakuan, maka dilanjutkan dengan Uji Jarak Berganda Duncan (UJBD). Hasil penelitian menunjukkan bahwa penggunaan bumbu memberikan perbedaan yang sangat nyata (P<0,01) terhadap total glukosa, total padatan terlarut, berat jenis dan tingkat kecerahan wama. Penggunaan gula merah memberikan perbedaan yang sangat nyata (P<0,01) terhadap total glukosa, total padatan terlarut, berat jenis dan tingkat kecerahan wama. Kombinasi kedua perlakuan memberikan perbedaan yang nyata (P<0,05) terhadap total glukosa (47,55% sampai 65,62%), dan sangat nyata (P<0,01) terhadap total padatan terlarut (64,63 sampai 77,73 brix), berat jenis (1,29 sampai 1,40) dan tingkat kecerahan wama (22,15 sampai 24,83). Konsentrasi bumbu dan gula merah yang tepat pada pembuatan kecap whey yaitu penggunaan bumbu 5% dan gula merah 50% dengan nilai total glukosa 57,53%, total padatan terlarut 69,93 brix, berat jenis 1,33 dan tingkat kecerahan wama 24,63. Kesimpulan yang diperoleh dari penelitian ini adalah semakin meningkatnya konsentrasi bumbu dan gula merah akan meningkatkan nilai total glukosa, total padatan terlarut dan berat jenis serta menurunkan nilai tingkat kecerahan wama kecap whey. Disarankan agar dilakukan penelitian lebih lanjut untuk mengetahui daya simpan kecap whey selama penyimpanan dan pemasaran pada suhu kamar